Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Three-year Open-label Extension of Subcutaneous Secukinumab in Active Lupus Nephritis
jRCT2021220032Completed
- Sponsor
- Novartis
- Start
- Oct 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Open-label, single-arm trial of secukinumab in lupus nephritis (LN), sponsored by Novartis. Primary endpoint: Complete Renal Response (CRR). Started Oct 2022; status: completed.
02
Drugs
secukinumab
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on jRCT2021220032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021220032.